SMAD4 and intrahepatic cholangiocarcinoma: Interestingly, Smad4 was found to be overexpressed in most extrahepatic cholangiocarcinoma patients [33], whereas the inactivation of Smad4 was identified in intrahepatic cholangiocarcinoma [34], which might be due to tumor heterogeneity.